Pegcantratinib - Sienna Biopharmaceuticals

Drug Profile

Pegcantratinib - Sienna Biopharmaceuticals

Alternative Names: CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class Antipsoriatics; Carbazoles; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis; Pruritus
  • Discontinued Neuropathic pain

Most Recent Events

  • 01 Nov 2017 Chemical structure information added
  • 01 Oct 2017 Phase-II clinical trials in Pruritus in USA (Topical)
  • 07 Sep 2017 Sienna Biopharmaceuticals plans a phase IIb trial for Plaque psoriasis by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top